Increase FiO2

PreclinicalSmall molecule

UUniversity Hospitals Cleveland Medical Center

Increase FiO2 is one of 4 small molecule programs targeting Thoracic Surgery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thoracic SurgeryTerminated

Thoracic SurgeryPreclinical

Terminated

Competition

Competitive Landscape

5 competitors in Thoracic Surgery

#DrugCompanyPhaseTrials

Dexmedetomidine Hydrochloride

Pfizer

Preclinical

1 2

S-Ketamine

PPeking University First Hospital

Preclinical

1 3

Vasoconstrictor Agents

UUniversity Hospitals Cleveland Medical Center

Preclinical

1 4

Increase FiO2

UUniversity Hospitals Cleveland Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thoracic Surgery1 trial

Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery

Terminated·UUniversity Hospitals Cleveland Medical Center·N/A·NCT01866657·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Increase FiO2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Increase FiO2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Increase FiO2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospitals Cleveland Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospitals Cleveland Medical Center

Increase FiO2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thoracic Surgery1 trial

References

Drug Info

Quick Facts

Related News